Breast Cancer - Board Review Summary
PART I - INVASIVE NODE-NEGATIVE: WHOLE-BREAST FRACTIONATION
Early Invasive Breast After Lumpectomy: Management Paradigm + Dose Anchors
| Scenario | Board-management answer | Dose anchors / caveats |
|---|---|---|
| Default breast conservation | Lumpectomy with negative margins, whole-breast RT, endocrine/systemic therapy by biology, and boost based on recurrence risk. | 40 Gy / 15 or 42.56 Gy / 16; sequential boost 10-16 Gy / 5-8 for young age, high grade, close/positive-re-excised margin, LVSI, TNBC/HER2+ biology, or extensive intraductal component. |
| Selected 5-fraction WBI | Useful for appropriately selected early-stage patients when anatomy/constraints are acceptable and boost strategy is not driving the plan. | 26 Gy / 5 over 1 week is the preferred FAST-Forward regimen; 27 Gy / 5 and FAST 30 Gy / 5 weekly carry more late-effect concern. |
| Partial breast candidate | Best for low-risk, node-negative, small, margin-negative, usually ER+ tumors; avoid if nodes positive, margins positive, age <40, germline BRCA1/2, or diffuse/high-risk features. | Common options: 30 Gy / 5, 27 Gy / 5, 40 Gy / 15, 38.5 Gy / 10 BID, or brachy 34 Gy / 10 BID. Prefer daily/QOD over BID when using external beam. |
| RT omission candidate | Shared decision for older, low-risk HR+/HER2- patients with negative margins and reliable endocrine therapy adherence; local recurrence rises, OS generally does not change. | Most established for age >65-70; biologic selection studies support very low short-term IBR in luminal A / low-RS groups but randomized confirmation is still maturing. |
| SLNB omitted | If clinically/sonographically cN0, postmenopausal, HR+/HER2-, grade 1-2, and otherwise low risk, do not automatically compensate with axillary RT. | WBI is common in the randomized no-SLNB data; APBI can still be reasonable if all low-risk criteria remain intact after surgery. |
Surgical Margin Rule (Invasive): Per SSO/ASTRO guidelines, the standard for an adequate margin in invasive breast cancer undergoing whole-breast irradiation is "no ink on tumor." Wider margins do not significantly decrease recurrence risk.
Moderate Hypofractionation Is the Standard of Care
For whole-breast irradiation after lumpectomy, moderate hypofractionation is standard based on the OCOG and UK START trials.
Common regimens:
Common regimens:
- 42.56 Gy / 16 fx
- 40 Gy / 15 fx
- Traditional sequential boost: 10-16 Gy / 5-8 fx
Ultrahypofractionation: FAST and FAST-Forward
| Trial | Population | Regimens | Main result |
|---|---|---|---|
| FAST | Age >=50, pT1-2 <3 cm, N0, BCS, no chemo | 50 Gy / 25 vs 30 Gy / 5 weekly vs 28.5 Gy / 5 weekly | 10y IBTR: 0.7%, 1.4%, 1.7%; more moderate/marked normal tissue effects with the 5-fx weekly regimens, especially 30 Gy |
| FAST-Forward | pT1-3, pN0-1, BCS or mastectomy; about 25% received a boost | 40 Gy / 15 vs 27 Gy / 5 vs 26 Gy / 5 over 1 week | 5y IBTR: 2.1%, 1.7%, 1.4%. 26 Gy / 5 had late effects closest to 40/15 and is the preferred 5-fx regimen |
Key board takeaway: 26 Gy / 5 is the FAST-Forward regimen that moved into mainstream practice. 27 Gy / 5 had more late normal-tissue effects, and 30 Gy / 5 weekly from FAST also looked less attractive from a late-toxicity standpoint.
Real-World 5-Fraction Experience
| Series | Population / regimen | Outcome |
|---|---|---|
| Institut Curie | 396 pts, node-negative, age >70 or disabling comorbidity; 5 fx / 5 days or 5 fx / 5 weeks | 2y LRFS 98.4% and 99.2%; sequential boost and 5.7 Gy weekly fractions increased fibrosis risk |
| MSKCC FAST-Forward + boost | 311 pts; 54% got boost 5.2 Gy x 1, 9% got 5.2 Gy x 2 | Acute G3 toxicity 4.5%; late G3 toxicity 4%; boost increased both acute and late toxicity |
PART II - BOOST DELIVERY AND SIB
Boost Strategy: Management Paradigm + Dose Anchors
| Clinical question | Practical answer | Dose anchors / caveats |
|---|---|---|
| Who gets boost? | Favor boost for higher in-breast recurrence risk: younger age, high grade, close margins, LVSI, TNBC/HER2+, extensive DCIS/EIC, or uncertain cavity risk. | Classic sequential boost 10-16 Gy / 5-8; tailor to margin status, age, cosmesis, and tumor-bed certainty. |
| Moderate-hypo WBI + boost | Sequential boost is the cleanest evidence base; concomitant boost is now reasonable in selected patients. | Example SIB: 40 Gy / 15 with boost to about 48 Gy; RTOG 1005 supports moderate-hypo SIB non-inferiority. |
| 5-fraction WBI + boost | Use cautiously; the optimal 5-fraction boost strategy is unsettled, especially for young or high-risk patients. | Examples include sequential 5.2 Gy x 1-2 or investigational SIB to about 30-33 Gy / 5; watch cosmesis/fibrosis. |
| Oncoplastic cavity uncertainty | Review pre-op imaging, operative note, clips, seroma, and pathology; if cavity cannot be localized safely, omit or broaden judiciously rather than guessing a high-dose boost. | Clips before tissue rearrangement are high value; avoid excessive boost volume when cosmesis is the limiting toxicity. |
Classic Trials Used Sequential Boost
The foundational moderate hypofractionation trials generally used either no boost or a sequential conventional-fraction boost, not SIB. That matters when extrapolating FAST-Forward or older hypofractionation data to modern SIB practice.
Concomitant / Simultaneous Integrated Boost Trials
| Study | Design | Main result | Takeaway |
|---|---|---|---|
| NRG RTOG 1005 | Higher-risk breast conservation population; moderate hypo with concomitant boost vs conventional / sequential strategy | IBR about 2.0% vs 1.9%; prespecified non-inferiority met | SIB with moderate hypofractionation is reasonable |
| IMPORT High / HYPOSIB era | Concomitant boost strategies during WBI | Overall reassuring for selected moderate-hypofractionated boost approaches | Boost can be integrated, but regimen choice matters |
| Tata Memorial SIB | Fast and Fast-Forward-style WBI with cumulative SIB doses 32-33 Gy / 5 fx | Cosmetic worsening increased over time | Ultrahypofractionated SIB remains cosmetically concerning |
| Mayo prospective trial | 40 Gy / 15 with SIB to 48 Gy vs 25 Gy / 5 with SIB to 30 Gy | Prospective comparison underway in modern practice | Important because boost strategy in 5-fx WBI is still unsettled |
Current practical view: moderate hypofractionated WBI +/- boost is established. Optimal boost strategy with 5-fraction WBI is still an open question, especially in younger patients and higher-risk biology.
PART III - PARTIAL BREAST IRRADIATION (PBI / APBI)
Partial Breast Irradiation: Management Paradigm + Dose Anchors
| Scenario | Use / avoid | Dose anchors / planning pearls |
|---|---|---|
| Favorable invasive cancer | Strongest fit: age >=40, small node-negative ER+ grade 1-2 tumor, negative margins, limited LVSI, and no high-risk genetic or diffuse pattern. | 30 Gy / 5 QOD/daily, 27 Gy / 5, or 40 Gy / 15; keep ipsilateral breast V50% ideally <50%. |
| DCIS | Reasonable for favorable DCIS with negative margins; more cautious for high-grade/larger DCIS; avoid with positive margins, age <40, or BRCA1/2. | Same practical external-beam schedules as invasive PBI; B39 DCIS subset was reassuring but underpowered. |
| Higher-risk features | Grade 3, ER-negative, larger size, lobular histology, or LVSI push toward conditional use or WBI depending on full context. | If normal-tissue constraints are hard with 27-30 Gy / 5, consider a lower-dose 5-fx approach only in very low-risk situations or default to WBI. |
| IORT | Not a routine substitute for standard PBI/WBI outside trial/registry-style use. | Single-fraction 20-21 Gy has convenience appeal but weaker recurrence-control confidence than modern external-beam/interstitial PBI. |
Three Common PBI Frameworks
| Type | Typical dose style | Treatment length |
|---|---|---|
| Accelerated PBI | 3.4-6 Gy per fraction | Usually 5 days |
| Intraoperative PBI | 20-21 Gy x 1 | 1 day, pre-surgical closure |
| Moderately fractionated PBI | 2.6-2.7 Gy per fraction | 15-16 fractions |
Randomized APBI Data
| Trial | APBI result | WBI result | Comment |
|---|---|---|---|
| NIO Budapest | ~5.5% | ~4.6% | Non-inferiority in selected low-risk population |
| University of Florence | ~3.7% | ~2.5% | Very favorable selected-stage I ER+ population |
| GEC-ESTRO | 1.9% | 1.7% | Strong support for interstitial APBI in selected pts |
| OCOG RAPID | 3.0% | 2.8% | Control similar, but RAPID historically raised cosmesis concerns |
| SHARE | ~1% | ~1% | Another favorable selected-population result |
NSABP B39 / RTOG 0413 intentionally enrolled a broader, higher-risk population and did not meet equivalence. Ten-year IBR was 4.6% with APBI vs 3.9% with WBI (HR 1.2, 90% CI 0.94-1.58). This is why APBI is best viewed as a strategy for carefully selected lower-risk patients, not a universal WBI replacement.
Current APBI Schedules to Know
| Schedule | Context |
|---|---|
| 38.5 Gy / 10 fx BID | Classic APBI schedule (e.g. B39) |
| 34 Gy / 10 fx BID | Brachy-based APBI |
| 30 Gy / 5 fx | Florence-style APBI, often QOD or daily |
| 27 Gy / 5 fx | Modern external-beam APBI option |
| 40 Gy / 15 fx | IMPORT LOW style moderate-fractionation partial-breast approach |
Planning pearl: for external-beam APBI in 27-30 Gy / 5, careful dosimetry is essential. A practical planning constraint is ipsilateral breast V50% <50%. If constraints are difficult, consider 26 Gy / 5 in very low-risk situations.
PART IV - OMISSION OF RT IN LOW-RISK INVASIVE CANCER
What the Omission Trials Actually Show
| Trial | Population | RT | No RT | Takeaway |
|---|---|---|---|---|
| CALGB 9343 | Age >70, stage I, HR+ | Local-regional recurrence 1.9% | 10% | Much higher local recurrence without RT, but no OS difference |
| PRIME II | Age >65, HR+, low-risk | Local-regional recurrence 0.9% | 9.8% | Same message: RT improves local control, not survival |
Important PRIME II nuance: omission looked less favorable in tumors with poor ER expression and in patients who were non-adherent with endocrine therapy. If endocrine therapy is not likely to be taken consistently, the case for omitting RT weakens.
Why RT Still Matters Even in Favorable Patients
EBCTCG 2011 showed that after breast-conserving surgery, RT reduced 10-year any first recurrence from 35% to 19.3% and reduced 15-year breast-cancer mortality from 25.2% to 21.4%. A practical way to interpret the EBCTCG data is that if the absolute 10-year recurrence reduction is under about 10%, survival benefit becomes hard to show, which is why modern omission strategies focus on extremely favorable biology.
Genomic / Biologic De-escalation Era
| Study | Selection | IBR |
|---|---|---|
| IDEA | Oncotype RS <18, pT1N0, endocrine therapy intended | 3.2% at 4 years |
| LUMINA | Luminal A by IHC/Ki67, pT1N0, grade 1-2, HR+/HER2- | 2.3% at 5 years |
| PRECISION | PAM50 low-risk biology | 0.3% at 2.24 years |
Current omission view: women age >65-70 with negative margins, strong endocrine therapy commitment, and very favorable luminal biology are the best-established candidates. Broader biologically guided omission is promising but still being tested in DEBRA, PRIMETIME, and EXPERT.
PART V - OMISSION OF SLNB AND RT IMPLICATIONS
No-SLNB Trials
| Trial | Eligibility | Node positivity in SLNB arm | Axillary / in-breast outcomes |
|---|---|---|---|
| SOUND | cN0 by axillary US, cT1 <2 cm, BCT + RT | 13.7% | Ipsilateral axillary recurrence 0.7%; IBR 0.8% |
| INSEMA | cN0 by axillary US, cT1-2 <5 cm, BCT + RT | 15.1% | Ipsilateral axillary recurrence 0.8%; IBR 1.0% |
| Dutch BOOG | cN0 by axillary US, cT1-2 <5 cm, BCT + RT | 13.7% | Ipsilateral axillary recurrence 1.0%; IBR 1.0% |
INSEMA RT detail: about 50% of patients received potentially therapeutic incidental dose to level I axilla. Even so, omitting SLNB during BCS does not require compensation by escalated axillary RT when whole-breast RT is being given.
Practical Omission-of-SLNB Framework
Key features:
- Age >50 and postmenopausal
- cT1N0 with node-negative axillary US
- HR+/HER2-, grade 1-2
- Agreeable to whole-breast RT and endocrine therapy
Practical Approach
For carefully selected patients age 50-69 without SLNB, we favor pre-op multidisciplinary review, cN0 confirmation by axillary imaging, luminal A-like biology, ET commitment, and then APBI post-op if all low-risk features hold. If any low-risk criterion is lost, default back toward WBI rather than intentionally treating the axilla.
PART VI - DCIS
DCIS: Management Paradigm + Dose Anchors
| Scenario | Board-management answer | Dose anchors / caveats |
|---|---|---|
| Lumpectomy, most patients | BCS + RT reduces ipsilateral events across risk groups; endocrine therapy if ER+ reduces new breast events but does not replace RT for most patients. | WBI 40 Gy / 15 or 42.56 Gy / 16; conventional 50 Gy / 25 acceptable when needed. |
| Non-low-risk DCIS | Consider tumor-bed boost for young age, high grade, comedo necrosis, larger size, close margins, or symptomatic/palpable presentation. | BIG/TROG-style boost 16 Gy / 8; common practical boost 10-16 Gy depending on WBI fractionation and risk. |
| Good-risk observation | Observation after lumpectomy is a shared decision only for very favorable DCIS; recurrence risk remains meaningful even in "good-risk" cohorts. | Best fit: screen-detected, small, grade 1-2, margins >2-3 mm, age >50, ER+, reliable surveillance/endocrine discussion. |
| APBI for DCIS | Reasonable in selected favorable DCIS with negative margins; avoid for positive margins, age <40, BRCA1/2, or diffuse/high-risk extent. | 30 Gy / 5, 27 Gy / 5, 40 Gy / 15, or brachy-style schedules; confirm cavity and calcification extent carefully. |
| Mastectomy for DCIS | Usually no PMRT after mastectomy; discuss only for unusual unresectable positive margin or very high-risk chest-wall recurrence concern. | Re-excision is preferred when feasible; RT decisions are individualized and uncommon. |
Surgical Margin Rule (DCIS): Per SSO/ASTRO guidelines, a negative margin of ≥ 2 mm is the standard to minimize IBTR for pure DCIS when WBI is planned. Unlike invasive cancer, "no ink on tumor" is inadequate for DCIS and routinely warrants re-excision.
Clinical Risk Stratification Still Matters
| Low-risk features | High-risk features |
|---|---|
| Screen-detected, grade 1-2, cribriform/papillary, ER/PR+, size <25 mm, age >50, margins >2 mm | Palpable or bloody nipple discharge, grade 3, comedo/solid, ER/PR-, size >25 mm, age <50, positive/close margins (<2 mm) |
Randomized RT Benefit in DCIS
EBCTCG meta-analysis of phase III trials of BCS +/- RT for DCIS showed an absolute 15.2% reduction in 10-year ipsilateral breast events with RT and a relative reduction of about 54% (HR 0.46), with no OS difference. Importantly, many patients on the legacy trials were not truly "ultra-low risk."
ECOG 5194 and RTOG 9804
| Study | Population | Main result |
|---|---|---|
| ECOG 5194 | Observation after lumpectomy with margins >=3 mm; cohort 1 low-risk NG1-2 <2.5 cm, cohort 2 grade 3 <1 cm | 12.3y ipsilateral recurrence 14.4% in low-risk cohort and 24.6% in high-risk cohort |
| RTOG 9804 | "Good-risk" DCIS randomized to RT vs observation | RT significantly reduced ipsilateral recurrence; observation arm still had substantial recurrence risk |
Board pearl: even "good-risk" DCIS is not zero-risk DCIS. ECOG 5194 and RTOG 9804 are the key reminders that observation after lumpectomy may still carry meaningful long-term recurrence rates.
DCIS Biosignatures
| Assay | Key point |
|---|---|
| Oncotype DCIS Score | Validated as a prognostic assay; OCOG ELISA is prospectively evaluating lumpectomy alone for DCIS with predicted 10y IBR risk <10% |
| DCISionRT | Low-risk DS <3 had little apparent RT benefit; elevated-risk DS >3 had large recurrence reduction with RT |
DCISionRT numbers to memorize: in the development/validation cohort, low-risk patients had all-event IBR about 8% vs 7% with and without RT, whereas elevated-risk patients had 23% vs 11%. Invasive-event rates were 15% vs 9% in elevated-risk patients. The assay also reclassified about 50% of clin-path "low-risk" patients upward.
DCIS Boost and APBI
Boost evidence is less mature in DCIS than in invasive cancer because the older RT-benefit trials used boost infrequently or not at all.
BIG 3-07 / TROG 07.01 randomized non-low-risk DCIS to boost 16 Gy / 8 fx vs none and to 42.56 Gy / 16 vs 50 Gy / 25; there was no difference in WBI outcome by fractionation.
For APBI in DCIS, the B39 DCIS subset was reassuring: 10y IBTR 6.5% with WBI vs 6.0% with APBI, but the subset was not powered for definitive equivalence conclusions.
BIG 3-07 / TROG 07.01 randomized non-low-risk DCIS to boost 16 Gy / 8 fx vs none and to 42.56 Gy / 16 vs 50 Gy / 25; there was no difference in WBI outcome by fractionation.
For APBI in DCIS, the B39 DCIS subset was reassuring: 10y IBTR 6.5% with WBI vs 6.0% with APBI, but the subset was not powered for definitive equivalence conclusions.
PART VII - PMRT / RNI: WHEN AND WHAT TO TREAT
PMRT / RNI: Management Paradigm + Dose Anchors
| Scenario | Board-management answer | Dose anchors / target notes |
|---|---|---|
| pN+ after upfront surgery | RNI/PMRT is recommended for most node-positive patients; omission is only for deliberately selected very low-risk biology/anatomy. | Breast/CW + retained axilla + SCV/infraclav + IMNs when giving true RNI; dose 50 Gy / 25, 42.56 Gy / 16, 43.5 Gy / 15, or selected 40 Gy / 15. |
| 1-3 positive nodes | Modern default favors RNI, especially young age, larger tumor, LVSI, high grade, medial/central tumor, TNBC/HER2+, multiple nodes, or limited axillary surgery. | IMN inclusion is part of effective RNI; individualize if cardiac/lung tradeoff is extreme or biologic recurrence risk is very low. |
| T3-4, positive margin, or skin/chest wall risk | PMRT even with node-negative disease when recurrence risk is high; T4/inflammatory disease needs comprehensive locoregional treatment. | Consider chest wall/scar boost for T4, close/positive margins, gross residual, or high-risk skin involvement: often 10-16 Gy after 50 Gy-class treatment. |
| Reconstruction | Moderate hypofractionation is supported, but coordinate with plastics and respect implant/expander geometry, skin dose, and complication risk. | 42.56 Gy / 16 is a common practical choice; bolus is not routine unless skin/superficial margin/dermal lymphatic risk requires it. |
| Technique / OARs | Use CT-based planning; DIBH for left-sided cases when it reduces heart/lung dose; IMRT/VMAT/protons only when they improve coverage/OAR balance. | Keep heart/lung/contralateral breast ALARA; practical PMRT goals include left heart mean ideally ≤3 Gy and ipsilateral lung V20 ≤35% when feasible. |
What Is RNI?
Regional nodal irradiation means treating the retained axilla, supraclavicular nodes, and internal mammary nodes. The internal mammary chain is a core component of true regional treatment.
Historical PMRT / RNI Trials
The 1997 British Columbia and DBCG 82b/82c trials established the historical PMRT paradigm, with 9-20% absolute 10-year OS gains despite older systemic therapy and less adequate axillary surgery than modern practice. Importantly, the RT fields in those studies treated chest wall + axilla + supraclavicular + IMN.
Modern Evidence for 1-3 Positive Nodes
| Trial | Effect of RNI / PMRT |
|---|---|
| EBCTCG 2014 | For 1-3 positive nodes after mastectomy, PMRT improved local control, overall recurrence, and long-term survival |
| NCIC MA.20 | LRR 6.8% vs 4.3%; distant DFS 82.4% vs 86.3%; DFS 77% vs 82% |
| EORTC 22922/10925 | LRR 9.5% vs 8.3%; distant DFS 75% vs 78%; DFS 69.1% vs 72.1% |
| EBCTCG 2023 RNI meta-analysis | Supports reductions in recurrence and breast-cancer mortality with modern regional treatment |
Board Exam Nodal Decision Matrix (1-3 Positive Nodes):
- OMIT RNI (Z0011 Paradigm): 1-2 positive sentinel nodes, T1-T2 tumor, lumpectomy, clinically N0 pre-op, receiving whole breast RT + systemic therapy. The ratio of positive to removed nodes does not matter here.
- ADD RNI (MA.20 Paradigm): High-risk features (young age, grade 3, ER-, LVSI, inner quadrant), or >20% positive node ratio if an ALND was performed.
- ypN0 post-NAC (B-51 Paradigm): Omission of RNI is standard for cN1 converted to ypN0, but strongly consider RNI if high residual breast burden or high-risk biology remains.
Why IMNs Matter
- IMN involvement is common, especially in axillary node-positive patients.
- Tumor location influences IMN risk.
- Veronesi's classic series showed IMN involvement around 20%.
Modern IMN Data
| Study | Design | Takeaway |
|---|---|---|
| KROG IMN | Randomized breast/CW/SCL +/- IMNI in pN+ disease | Modest absolute gains across endpoints; reinforces that IMNI matters, even if effect size is not huge |
| DBCG IMN prospective | Right-sided pts received IMN RT, left-sided did not | Prospective data also support IMNI as beneficial in node-positive disease |
| DBCG IMN 2 | Prospective study updated 2025 | Keeps the field moving toward routine IMN inclusion in appropriate node-positive patients |
PART VIII - PMRT / RNI FRACTIONATION, DE-ESCALATION, POST-NAC, AND PROTONS
Post-NAC / Fractionation / Proton Paradigm + Dose Anchors
| Scenario | Practical answer | Dose / decision anchor |
|---|---|---|
| cN0 -> ypN0 | No routine RNI/PMRT unless other high-risk features dominate. | Use standard breast/CW indications; do not escalate solely because NAC was given. |
| cT1-3N1 -> ypN0 | B-51 supports omission of RNI for many patients; review pre-chemo imaging and biology before de-escalating. | Omission is most comfortable with breast pCR/near-pCR and TNBC/HER2+ response; lean RNI for HR+/HER2-, no breast pCR, high RCB, young age, or suspicious residual anatomy. |
| cN2-3, cT4, or ypN+ | RNI/PMRT remains recommended even after good response. | Breast/CW + comprehensive nodes, usually 42.56 Gy / 16 or 50 Gy / 25; boost gross residual/undissected nodal disease as needed. |
| Hypofractionation choice | Moderate hypofractionation is now supported for PMRT/RNI, including reconstructed patients; ultrahypofractionated nodal RT remains less mature. | Common: 42.56 Gy / 16; alternatives 43.5 Gy / 15 or 40 Gy / 15. Five-fraction nodal strategies are not routine board-defaults. |
| Protons | Consider only when photon plans cannot meet target/OAR goals, especially comprehensive left-sided IMN/RNI; not routine for everyone. | Dosimetry improves, but long-term major-cardiac-event superiority is pending and rib fracture/dermatitis/reconstruction issues still matter. |
Moderate Hypofractionation for RNI Is Supported
| Trial | Conventional arm | Hypofractionated arm | Key point |
|---|---|---|---|
| Beijing | 50 Gy / 25 | 43.5 Gy / 15 | Comparable local control and toxicity |
| FABREC RT | 50 Gy / 25 | 42.56 Gy / 16 | Implant reconstruction population; no clear penalty for hypofractionation |
| CHARM | 50 Gy / 25 | 42.56 Gy / 16 | Reconstruction population; similar outcomes and complications |
| DBCG SKAGEN 1 | 50 Gy / 25 | 40 Gy / 15 | No significant difference in lymphedema, LRR, DM, or DFS |
Practical regimen note: 42.56 Gy / 16 fx is a commonly used PMRT / RNI moderate-hypofractionation option. One 40 Gy / 15 dataset has raised a puzzling breast-cancer mortality signal, so not all moderate-hypofractionated regimens are viewed equally.
Ultrahypofractionated RNI
Early 5-year PRO data comparing 40 Gy / 15 with 26 Gy / 5 or 27 Gy / 5 are interesting, with no brachial plexopathy seen and no clear lymphedema penalty. But available ultrahypofractionated nodal data are not yet practice-changing, partly because IMNs and low axilla were often under-treated relative to modern standards.
Can We De-escalate RNI in Luminal A / Low-RS N1 Disease?
Not all patients with 1-3 positive nodes benefit equally from RNI. Planned analysis of MA.20 suggested larger benefit in ER/PR-negative disease, and luminal A biology plus low Oncotype RS may identify patients with such low baseline LRR that RNI benefit becomes small. This is exactly what CCTG MA39 (Tailor RT) is testing.
Tailor RT (MA39)
MA39 randomizes women age >40 with 1-3 positive nodes (or pT3N0 / N1mic), ER+ and/or PR+, HER2-negative, and Oncotype RS <=25 to endocrine therapy +/- RNI. This is the main de-escalation trial to know for biologically low-risk node-positive disease.
Post-Neoadjuvant RNI: B-51 / RTOG 1304
NSABP B-51 / RTOG 1304 randomized cT1-3N1 biopsy-proven node-positive patients who became ypN0 after NAC to RNI vs no RNI. At median follow-up around 5 years, there was no difference in any endpoint.
Practical framework:
- cN0 / ypN0: observation
- cN1 / ypN0: review pre-chemo imaging carefully; omission is reasonable for many, especially TNBC / HER2+ with strong breast response or pCR
- Strongly consider RNI in HR+/HER2- disease and in those without breast pCR, especially RCB-II/III
- cN2-3 / ypN0: RNI
- cN+ / ypN+: RNI
Where Do We Stand on Protons?
| Study | Signal | Takeaway |
|---|---|---|
| DFCI phase II proton RNI | No grade 3+ pneumonitis; mean heart dose 0.5 Gy; LAD 1.16 Gy; rib fractures still occurred | Dosimetrically excellent, but not toxicity-free |
| Mayo inflammatory BC IMPT | 21% rib fracture rate in a small series; frequent replanning | Real toxicity concerns persist |
| RADCOMP early data | Better dosimetry, but no significant HRQOL benefit so far; photon mean whole-heart dose still low (2.99 Gy) | Carefully planned photon RNI remains standard while waiting for long-term MCE results |
PART IX - METASTATIC DISEASE: OLIGOMETASTATIC AND OLIGOPROGRESSIVE
Metastatic Breast Cancer: Management Paradigm + Dose Anchors
| Scenario | Practical answer | Dose anchors / caveats |
|---|---|---|
| Diffuse symptomatic disease | Palliative RT for pain, bleeding, mass effect, fracture risk, cord/nerve compression, or local symptoms; systemic therapy drives survival. | 8 Gy / 1, 20 Gy / 5, or 30 Gy / 10; tailor for retreatment, cord/cauda, fracture stabilization, and prognosis. |
| De novo primary in metastatic disease | Do not assume curative local therapy improves survival; treat breast/axilla for symptoms, durable local control, or carefully selected oligometastatic context. | Use standard breast/chest wall regimens if local-control intent is chosen; avoid delaying effective systemic therapy. |
| Fungating / bleeding mass | Palliative RT offers excellent local symptom control (bleeding, discharge, pain) for intact primary tumors that fail systemic therapy. | HYPORT B: 26 Gy / 5 to whole breast + supraclavicular region with SIB 32 Gy to gross disease. |
| Oligometastatic disease | Metastasis-directed ablation is not routine standard after negative randomized breast-specific data; consider trial or highly selected durable-control scenarios. | SBRT dose is site-specific; the key board answer is selection and systemic-therapy context, not one universal dose. |
| Oligoprogression | More plausible when most disease is controlled on a valuable systemic line, especially HR+/HER2- on endocrine/CDK4/6 or selected HER2+ disease. | SBRT to all progressing sites may extend time on current systemic therapy in selected cases, but randomized breast-specific evidence remains limited. |
Diffuse Metastatic Disease: Standard Palliative RT
For broadly metastatic symptomatic disease, breast RT remains palliative rather than ablative. Common high-yield palliative regimens include 30 Gy / 10, 20 Gy / 5, and 8 Gy / 1.
Palliative Primary Irradiation
HYPORT Trials: For painful, bleeding, or fungating intact breast masses in the metastatic setting, high-dose hypofractionation is highly effective. HYPORT B utilized 26 Gy / 5 fx to the whole breast and supraclavicular region, with an SIB of 32 Gy to the gross disease. This significantly reduced ulceration, bleeding, and discharge while improving overall quality of life.
Oligometastatic Breast Cancer
NRG BR002 tested ablative local therapy (SBRT or surgery) for patients with 1-4 metastatic lesions. The bottom line is that metastasis-directed therapy in oligometastatic breast cancer is not currently standard of care, because randomized evidence has not shown a clear PFS benefit or reduced emergence of new metastases.
Oligoprogression: Definition and Incidence
Oligoprogression means a patient with otherwise controlled widespread metastatic disease on systemic therapy develops only a small number of progressing or new lesions while most sites remain stable or responding.
It appears to be especially relevant in ER+/HER2- disease, where rates of more than 20% have been described at some point in the disease course.
It appears to be especially relevant in ER+/HER2- disease, where rates of more than 20% have been described at some point in the disease course.
Does Treating Oligoprogression Help?
| Study | Population | Main result |
|---|---|---|
| CURB | 47 metastatic breast cancer pts with <=5 oligoprogressive sites randomized to SOC +/- SBRT | No PFS difference in breast cohort: 4.2 vs 4.4 months; about one-third were TNBC |
| David et al. 2025 | Single-arm prospective series | Median EFS 5.2 months; median PFS 10.4 months; signal seemed strongest in HR+/HER2- pts on ET + CDK4/6 |
Current interpretation: breast oligoprogression is a much more plausible SBRT niche than breast oligometastatic disease generally, but evidence remains limited. Future studies should focus on patients with long natural histories, especially HR+/HER2- and perhaps HER2+ disease, where staying on an effective systemic line longer could matter.
PART X - ORAL-BOARD WORKUP AND SPECIAL SCENARIOS
Initial Workup Script
Clinic flow: history with menopausal status, pregnancy possibility, prior RT, autoimmune/collagen vascular disease, implants/reconstruction goals, family history, and endocrine therapy feasibility.
Exam: bilateral breast, skin/nipple, chest wall, axillary/supraclavicular/infraclavicular nodes, arm edema and baseline shoulder function.
Imaging/pathology: diagnostic mammogram with appropriate views, targeted ultrasound of breast/axilla, image-guided core biopsy with clip placement, ER/PR/HER2, grade, LVSI, and selective MRI for extent, lobular histology, occult primary, discordant imaging/pathology, very dense breasts, or surgical planning.
Systemic staging: usually not for asymptomatic stage I-II; obtain CT/bone scan or PET/CT for stage III, inflammatory, symptoms, abnormal labs, or high-risk biology where results would change management.
Exam: bilateral breast, skin/nipple, chest wall, axillary/supraclavicular/infraclavicular nodes, arm edema and baseline shoulder function.
Imaging/pathology: diagnostic mammogram with appropriate views, targeted ultrasound of breast/axilla, image-guided core biopsy with clip placement, ER/PR/HER2, grade, LVSI, and selective MRI for extent, lobular histology, occult primary, discordant imaging/pathology, very dense breasts, or surgical planning.
Systemic staging: usually not for asymptomatic stage I-II; obtain CT/bone scan or PET/CT for stage III, inflammatory, symptoms, abnormal labs, or high-risk biology where results would change management.
Genetic / Biology Triggers
Think genetics referral/testing for young age at diagnosis, triple-negative disease, ovarian/pancreatic/high-risk prostate family history, Ashkenazi Jewish ancestry, bilateral/multiple primaries, male breast cancer, or strong family clustering. Biology changes RT decisions indirectly by shaping systemic therapy, recurrence risk, and appropriateness of APBI/omission.
Ipsilateral Recurrence & Re-irradiation: Management Paradigm
| Scenario | Board-management answer | Dose / trial anchor |
|---|---|---|
| Salvage breast conservation | Salvage mastectomy is the historical standard for local recurrence after prior RT. However, for favorable recurrences (≤3 cm, non-multicentric), a second lumpectomy followed by partial breast re-irradiation is a safe, standard alternative. | RTOG 1014: 45 Gy / 30 fx (1.5 Gy BID, ≥6 hours apart) using 3D-CRT to the partial breast. |
Inflammatory Breast Cancer: Management Paradigm + Dose Anchors
| Step | Board-management answer | Dose / planning anchor |
|---|---|---|
| Diagnosis | Clinical diagnosis: rapid breast erythema/edema/peau d'orange involving a substantial portion of breast, supported by invasive carcinoma; dermal lymphatic invasion helps but is not required. | Stage as at least T4d; document skin extent photographically and on exam before treatment. |
| Initial management | Neoadjuvant systemic therapy first, tailored by HER2/HR/TNBC biology; no upfront lumpectomy or skin-sparing approach. | Assess response clinically and radiographically; coordinate early with surgery and plastics. |
| Surgery | Modified radical mastectomy / mastectomy with axillary management after systemic therapy; immediate reconstruction is usually avoided. | Mark scars, drains, persistent skin change, and any unresected/residual nodal disease for RT planning. |
| Postoperative RT | Comprehensive PMRT/RNI to chest wall/skin and regional nodes, including SCV/axilla/IMNs when feasible. | Common anchor 50 Gy / 25 or selected moderate hypo; use bolus for dermal lymphatic/skin involvement or superficial-risk coverage; boost chest wall/scar/residual-risk region 10-16 Gy when indicated. |
Planning Guardrails
| Issue | Board-facing reminder |
|---|---|
| Left-sided breast / RNI | Use DIBH when it improves heart/lung dose. Review whole heart, LAD/LV when available, ipsilateral lung, contralateral breast/lung, humeral head/plexus, and thyroid for nodal plans. |
| Internal mammary nodes | Follow the vessels and pre-treatment imaging; first 3-4 interspaces are typical, but gross IMNs can sit outside atlas defaults. |
| Clipped node after NAC | Confirm clipped node removal when relying on nodal downstaging. If a suspicious clipped node remains, include it in target volumes or discuss surgical retrieval. |
| Bolus | Not routine for all PMRT. Use when skin, superficial margin, dermal lymphatic involvement, extensive LVI, or inflammatory presentation requires reliable skin dose. |
CROSS-CUTTING HIGH-YIELD POINTS
- Surgical margins (SSO/ASTRO): Invasive carcinoma = no ink on tumor. Pure DCIS = ≥ 2 mm.
- Oral-board workup: diagnostic mammogram/US, biopsy with clip, ER/PR/HER2, careful nodal exam/imaging, selective MRI, and distant staging only when stage/symptoms/high-risk features justify it.
- Genetics triggers: young age, TNBC, ovarian/pancreatic/prostate family history, Ashkenazi ancestry, bilateral/multiple primaries, or male breast cancer.
- Whole-breast standard: moderate hypofractionation with 40 Gy / 15 or 42.56 Gy / 16.
- FAST-Forward pearl: 26 Gy / 5 is the favored 1-week WBI regimen; 27 Gy / 5 had more late effects.
- Boost strategy: sequential boost remains the cleanest evidence base; SIB is reasonable with moderate hypofractionation but less settled with ultrahypofractionation.
- APBI: best-supported in carefully selected stage I, ER+/HER2-, low-risk patients.
- B39: did not meet equivalence overall, largely because it intentionally enrolled a broader-risk population.
- Omission of RT: most established in women age >65-70 with stage I, HR+ disease committed to endocrine therapy.
- EBCTCG 2011: RT after lumpectomy reduces recurrence and modestly reduces breast-cancer mortality.
- Genomic omission era: LUMINA, IDEA, and related studies support extremely low recurrence in selected luminal A / low-RS disease, but randomized confirmation is ongoing.
- SLNB omission: no-SLNB BCT trials with whole-breast RT have shown very low axillary recurrence.
- No-SLNB RT implication: do not intentionally treat the axilla just because SLNB was omitted if the patient otherwise fits a low-risk omission framework.
- DCIS: RT reduces ipsilateral events across low- and high-risk groups, but not OS.
- ECOG 5194: "good-risk" observation still carries substantial long-term recurrence risk.
- DCISionRT: may help identify who actually gains substantial benefit from RT.
- RNI target definition: retained axilla + supraclavicular + internal mammary nodes.
- 1-3 positive nodes: modern evidence supports RNI / PMRT.
- IMNs matter: omission of IMN coverage means you may not really be giving full RNI.
- Moderate hypofractionated PMRT/RNI is supported by randomized data, including reconstructed patients.
- B-51 / RTOG 1304: cN1 -> ypN0 after NAC is the major modern RNI de-escalation dataset; routine RNI is no longer automatic in all such patients.
- Inflammatory breast cancer: clinical diagnosis, neoadjuvant systemic therapy, modified radical mastectomy, and comprehensive PMRT/RNI with skin-dose attention.
- Bolus: not routine for all PMRT; use for skin involvement, superficial margin, dermal lymphatic involvement, extensive LVI, or inflammatory presentation.
- Protons: better dosimetry, but no proven short-term HRQOL advantage and nontrivial toxicity concerns remain.
- Oligometastatic breast cancer: MDT is not standard of care.
- Oligoprogression: promising concept, especially in HR+/HER2- disease, but not yet proven by strong randomized data.
CONSOLIDATED DOSE TABLE
| Setting | Dose / schedule | Comment |
|---|---|---|
| Moderate-hypo WBI | 40 Gy / 15 | Standard whole-breast regimen |
| Moderate-hypo WBI | 42.56 Gy / 16 | OCOG-style standard |
| Sequential boost | 10-16 Gy / 5-8 fx | Traditional add-on boost |
| DCIS non-low-risk boost | 16 Gy / 8 fx | BIG/TROG-style boost anchor; practical boost often 10-16 Gy |
| FAST-Forward WBI | 26 Gy / 5 | Preferred 5-fraction whole-breast option |
| FAST-Forward alternative | 27 Gy / 5 | Less favored because of late effects |
| FAST weekly | 28.5 Gy / 5 weekly | Older weekly 5-fx approach |
| FAST weekly | 30 Gy / 5 weekly | More late effects |
| Moderate-hypo SIB | 40 Gy / 15 with SIB to 48 Gy | Modern concomitant-boost example |
| 5-fx SIB example | 25 Gy / 5 with SIB to 30 Gy | Investigational / evolving boost strategy |
| Florence APBI | 30 Gy / 5 | Key external-beam APBI schedule |
| Modern APBI | 27 Gy / 5 | Common external-beam APBI option |
| Classic APBI | 38.5 Gy / 10 BID | B39-era schedule |
| Moderate-fractionated PBI | 40 Gy / 15 | IMPORT LOW-style partial-breast approach |
| PMRT / RNI conventional | 48-50 Gy / 24-25 | Historic standard |
| PMRT / RNI moderate hypo | 42.56 Gy / 16 | Common practical moderate-hypofractionated option |
| PMRT / RNI moderate hypo | 43.5 Gy / 15 | Beijing trial |
| PMRT / RNI moderate hypo | 40 Gy / 15 | Supported, though some clinicians view it more cautiously because of dataset-specific signals |
| Inflammatory / T4 chest wall + nodes | 50 Gy / 25 | Comprehensive PMRT/RNI anchor; selected moderate hypo by context |
| Chest wall / scar boost | +10-16 Gy | T4, close/positive margin, gross residual, or high-risk skin/scar region |
| PMRT skin bolus | Case-specific | Use for skin involvement, superficial margin, dermal lymphatic disease, extensive LVI, or inflammatory presentation; not routine for all PMRT |
| Left PMRT/RNI heart goal | Mean heart ideally ≤3 Gy | DIBH / technique selection benchmark; keep ALARA |
| PMRT/RNI ipsilateral lung goal | V20 ideally ≤35% | Common planning benchmark; individualize for anatomy and target coverage |
| Palliative metastatic RT | 30 Gy / 10 | Diffuse metastatic symptom control |
| Palliative metastatic RT | 20 Gy / 5 | Short palliative course |
| Palliative metastatic RT | 8 Gy / 1 | Single-fraction palliation |
| Palliative fungating mass | 26 Gy / 5 + SIB 32 Gy | HYPORT B regimen for bleeding/painful intact primary |
| Salvage partial breast re-RT | 45 Gy / 30 BID | RTOG 1014 regimen for recurrence after prior WBI (1.5 Gy/fx) |
KEY LANDMARK TRIALS (memorize)
| Trial | Disease / question | One-line takeaway |
|---|---|---|
| OCOG | Node-negative breast conservation | 42.56 Gy / 16 helped establish moderate hypofractionation |
| START A / B | Node-negative breast conservation | Moderate hypofractionation gives durable control and acceptable toxicity |
| FAST | Ultrahypofractionation | Weekly 5-fx regimens work, but late effects limit enthusiasm for 30 Gy |
| FAST-Forward | Ultrahypofractionation | 26 Gy / 5 became the key 1-week WBI regimen |
| RTOG 1005 | Concomitant boost | Moderate-hypofractionated WBI with SIB is a viable approach |
| BIG 3-07 / TROG 07.01 | DCIS boost / fractionation | Boost lowers recurrence in non-low-risk DCIS; moderate hypofractionation is acceptable |
| Florence | APBI | 30 Gy / 5 supports APBI in selected low-risk disease |
| GEC-ESTRO | APBI | Interstitial APBI can match WBI in selected patients |
| NSABP B39 / RTOG 0413 | APBI | Did not meet equivalence overall, mainly because it treated broader-risk patients |
| CALGB 9343 | RT omission | Older HR+ women can omit RT with higher local recurrence but no OS penalty |
| PRIME II | RT omission | Confirms the same low-risk elderly omission principle |
| EBCTCG 2011 | Post-lumpectomy RT benefit | RT reduces recurrence and modestly lowers breast-cancer mortality |
| LUMINA | Biologic omission | Selected luminal A patients have very low recurrence without RT |
| IDEA | Oncotype-based omission | Low RS plus favorable clinicopathologic features identify very low-risk patients |
| SOUND / INSEMA / BOOG | SLNB omission | Axillary recurrence remains very low with whole-breast RT in selected cN0 patients |
| ECOG 5194 | Observation for DCIS | Even low-risk DCIS has meaningful long-term recurrence risk without RT |
| RTOG 9804 | Good-risk DCIS | RT still significantly lowers ipsilateral recurrence |
| DCISionRT | DCIS biosignature | May identify who actually gains substantial benefit from RT |
| BC / DBCG 82b / 82c | Historic PMRT | Established survival benefit from chest wall + full nodal irradiation |
| EBCTCG 2014 | PMRT in 1-3 nodes | Supports PMRT benefit even with limited nodal burden |
| NCIC MA.20 | RNI after BCS | RNI improves LRR, distant DFS, and DFS |
| EORTC 22922/10925 | RNI / IM-MS | Confirms regional treatment benefit including IMN relevance |
| KROG IMN / DBCG IMN | Internal mammary RT | Support IMN treatment as a real component of effective RNI |
| Beijing / FABREC / CHARM / SKAGEN | PMRT/RNI hypofractionation | Modern randomized datasets support moderate hypofractionation, including reconstruction settings |
| B-51 / RTOG 1304 | Post-NAC ypN0 | Routine RNI is not mandatory for every cN1 -> ypN0 patient |
| RADCOMP | Photon vs proton RNI | Dosimetry favors protons, but patient-centered superiority has not yet been shown |
| NRG BR002 | Oligometastatic breast cancer | Metastasis-directed ablation is not yet standard of care |
| CURB | Oligoprogressive breast cancer | Randomized SBRT did not improve PFS in the breast subset |
| HYPORT B | Palliative fungating breast mass | 26 Gy / 5 (breast/SCV) + SIB 32 Gy improves local symptoms and QOL |
| RTOG 1014 | Ipsilateral recurrence re-irradiation | Partial breast re-irradiation (45 Gy / 30 BID) after 2nd lumpectomy is a safe alternative to salvage mastectomy |